Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 9.8% in December

Bone Biologics Co. (NASDAQ:BBLG) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 55,100 shares, an increase of 9.8% from the December 15th total of 50,200 shares. Based on an average daily volume of 224,100 shares, the short-interest ratio is presently 0.2 days. Currently, 10.3% of the company’s stock are short sold.

Bone Biologics Trading Up 2.2 %

Shares of NASDAQ BBLG traded up $0.02 during trading hours on Friday, hitting $0.98. The company had a trading volume of 26,414 shares, compared to its average volume of 197,204. Bone Biologics has a 1-year low of $0.80 and a 1-year high of $4.74. The firm’s 50 day moving average is $1.11 and its 200-day moving average is $1.43.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.